Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2007 (2007), Article ID 23812, 12 pages
http://dx.doi.org/10.1155/2007/23812
Review Article

PPARs in Alveolar Macrophage Biology

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109-2200, USA

Received 13 March 2007; Accepted 18 May 2007

Academic Editor: Jesse Roman

Copyright © 2007 Monica R. Smith et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. K. Glass and S. Ogawa, “Combinatorial roles of nuclear receptors in inflammation and immunity,” Nature Reviews Immunology, vol. 6, no. 1, pp. 44–55, 2006. View at Publisher · View at Google Scholar
  2. R. M. Touyz and E. L. Schiffrin, “Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications,” Vascular Pharmacology, vol. 45, no. 1, pp. 19–28, 2006. View at Publisher · View at Google Scholar
  3. F. Gizard, C. Amant, O. Barbier et al., “PPARa inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a,” Journal of Clinical Investigation, vol. 115, no. 11, pp. 3228–3238, 2005. View at Publisher · View at Google Scholar
  4. Q. N. Diep, F. Amiri, R. M. Touyz et al., “PPARa activator effects on Ang II-induced vascular oxidative stress and inflammation,” Hypertension, vol. 40, no. 6, pp. 866–871, 2002. View at Publisher · View at Google Scholar
  5. A. D. Burdick, D. J. Kim, M. A. Peraza, F. J. Gonzalez, and J. M. Peters, “The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation,” Cellular Signalling, vol. 18, no. 1, pp. 9–20, 2006. View at Publisher · View at Google Scholar
  6. A. Sugawara, K. Takeuchi, A. Uruno et al., “Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-? in vascular smooth muscle cells,” Endocrinology, vol. 142, no. 7, pp. 3125–3134, 2001. View at Publisher · View at Google Scholar
  7. M. J. Ryan, S. P. Didion, S. Mathur, F. M. Faraci, and C. D. Sigmund, “PPARγ agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice,” Hypertension, vol. 43, no. 3, pp. 661–666, 2004. View at Publisher · View at Google Scholar
  8. H. P. Koeffler, “Peroxisome proliferator-activated receptor γ and cancers,” Clinical Cancer Research, vol. 9, no. 1, pp. 1–9, 2003. View at Google Scholar
  9. M. H. Fenner and E. Elstner, “Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer,” Expert Opinion on Investigational Drugs, vol. 14, no. 6, pp. 557–568, 2005. View at Publisher · View at Google Scholar
  10. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar
  11. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar
  12. T. J. Standiford, V. C. Keshamouni, and R. C. Reddy, “Peroxisome proliferator-activated receptor-γ as a regulator of lung inflammation and repair,” Proceedings of the American Thoracic Society, vol. 2, no. 3, pp. 226–231, 2005. View at Publisher · View at Google Scholar
  13. A. Nencioni, F. Grünebach, A. Zobywlaski, C. Denzlinger, W. Brugger, and P. Brossart, “Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor γ,” Journal of Immunology, vol. 169, no. 3, pp. 1228–1235, 2002. View at Google Scholar
  14. J. Padilla, K. Kaur, H. J. Cao, T. J. Smith, and R. P. Phipps, “Peroxisome proliferator activator receptor-γ agonists and 15-deoxy-Δ12,14-PGJ2 induce apoptosis in normal and malignant B-lineage cells,” Journal of Immunology, vol. 165, no. 12, pp. 6941–6948, 2000. View at Google Scholar
  15. R. B. Clark, D. Bishop-Bailey, T. Estrada-Hernandez, T. Hla, L. Puddington, and S. J. Padula, “The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses,” Journal of Immunology, vol. 164, no. 3, pp. 1364–1371, 2000. View at Google Scholar
  16. R. Cunard, Y. Eto, J. T. Muljadi, C. K. Glass, C. J. Kelly, and M. Ricote, “Repression of IFN-γ expression by peroxisome proliferator-activated receptor γ,” Journal of Immunology, vol. 172, no. 12, pp. 7530–7536, 2004. View at Google Scholar
  17. X. Y. Yang, L. H. Wang, T. Chen et al., “Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor ? (PPAR?) agonists. PPAR? co-association with transcription factor NFAT,” Journal of Biological Chemistry, vol. 275, no. 7, pp. 4541–4544, 2000. View at Publisher · View at Google Scholar
  18. G. Woerly, K. Honda, M. Loyens et al., “Peroxisome proliferator-activated receptors a and ? down-regulate allergic inflammation and eosinophil activation,” Journal of Experimental Medicine, vol. 198, no. 3, pp. 411–421, 2003. View at Publisher · View at Google Scholar
  19. X. Zhang, M. C. Rodriguez-Galán, J. J. Subleski et al., “Peroxisome proliferator-activated receptor-? and its ligands attenuate biologic functions of human natural killer cells,” Blood, vol. 104, no. 10, pp. 3276–3284, 2004. View at Publisher · View at Google Scholar
  20. H. Sugiyama, T. Nonaka, T. Kishimoto, K. Komoriya, K. Tsuji, and T. Nakahata, “Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation,” European Journal of Immunology, vol. 30, no. 12, pp. 3363–3370, 2000. View at Publisher · View at Google Scholar
  21. J. Becker, C. Delayre-Orthez, N. Frossard, and F. Pons, “Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?” Fundamental & Clinical Pharmacology, vol. 20, no. 5, pp. 429–447, 2006. View at Publisher · View at Google Scholar
  22. C. Schachtrup, T. E. Scholzen, V. Grau et al., “L-FABP is exclusively expressed in alveolar macrophages within the myeloid lineage: evidence for a PPARa-independent expression,” The International Journal of Biochemistry & Cell Biology, vol. 36, no. 10, pp. 2042–2053, 2004. View at Publisher · View at Google Scholar
  23. C. Delayre-Orthez, J. Becker, I. Guenon et al., “PPARa downregulates airway inflammation induced by lipopolysaccharide in the mouse,” Respiratory Research, vol. 6, p. 91, 2005. View at Publisher · View at Google Scholar
  24. P. R. Devchand, H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez, and W. Wahli, “The PPARα-leukotriene B4 pathway to inflammation control,” Nature, vol. 384, no. 6604, pp. 39–43, 1996. View at Publisher · View at Google Scholar
  25. R. Paumelle, C. Blanquart, O. Briand et al., “Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-a via inhibition of the protein kinase C signaling pathway,” Circulation Research, vol. 98, no. 3, pp. 361–369, 2006. View at Publisher · View at Google Scholar
  26. T. L. Graham, C. Mookherjee, K. E. Suckling, C. N. A. Palmer, and L. Patel, “The PPARδ agonist GW0742X reduces atherosclerosis in LDLR-/- mice,” Atherosclerosis, vol. 181, no. 1, pp. 29–37, 2005. View at Publisher · View at Google Scholar
  27. P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, “PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–252, 1998. View at Publisher · View at Google Scholar
  28. G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors a and ? induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998. View at Publisher · View at Google Scholar
  29. L. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, “Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ,” Cell, vol. 93, no. 2, pp. 229–240, 1998. View at Publisher · View at Google Scholar
  30. E. D. Thomas, R. E. Ramberg, G. E. Sale, R. S. Sparkes, and D. W. Golde, “Direct evidence for a bone marrow origin of the alveolar macrophage in man,” Science, vol. 192, no. 4243, pp. 1016–1018, 1976. View at Publisher · View at Google Scholar
  31. P. B. Bitterman, L. E. Saltzman, S. Adelberg, V. J. Ferrans, and R. G. Crystal, “Alveolar macrophage replication. One mechanism for the expansion of the mononuclear phagocyte population in the chronically inflamed lung,” Journal of Clinical Investigation, vol. 74, no. 2, pp. 460–469, 1984. View at Google Scholar
  32. A. Blusse van Oud Alblas, B. van der Linden-Schrever, and R. van Furth, “Origin and kinetics of pulmonary macrophages during an inflammatory reaction induced by intravenous administration of heat-killed bacillus Calmette-Guerin,” Journal of Experimental Medicine, vol. 154, no. 2, pp. 235–252, 1981. View at Publisher · View at Google Scholar
  33. A. Blusse van Oud Alblas, H. Mattie, and R. van Furth, “A quantitative evaluation of pulmonary macrophage kinetics,” Cell and Tissue Kinetics, vol. 16, no. 3, pp. 211–219, 1983. View at Google Scholar
  34. P. Allavena, L. Piemonti, D. Longoni et al., “IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages,” European Journal of Immunology, vol. 28, no. 1, pp. 359–369, 1998. View at Publisher · View at Google Scholar
  35. S.-I. Hashimoto, M. Yamada, K. Motoyoshi, and K. S. Akagawa, “Enhancement of macrophage colony-stimulating factor-induced growth and differentiation of human monocytes by interleukin-10,” Blood, vol. 89, no. 1, pp. 315–321, 1997. View at Google Scholar
  36. R. A. Musson, “Human serum induces maturation of human monocytes in vitro. Changes in cytolytic activity, intracellular lysosomal enzymes, and nonspecific esterase activity,” American Journal of Pathology, vol. 111, no. 3, pp. 331–340, 1983. View at Google Scholar
  37. H. Tanaka, E. Abe, C. Miyaura, Y. Shiina, and T. Suda, “1α,25-dihydroxyvitamin D3 induces differentiation of human promyelocytic leukemia cells (HL-60) into monocyte-macrophages but not into granulocytes,” Biochemical and Biophysical Research Communications, vol. 117, no. 1, pp. 86–92, 1983. View at Publisher · View at Google Scholar
  38. D. W. H. Riches and M. J. Fenton, “Monocytes, macrophages, and dendritic cells of the lung,” in Murray and Nadel's Textbook of Respiratory Medicine, R. J. Mason, J. F. Murray, V. C. Broaddus, and J. A. Nadel, Eds., Elsevier Saunders, Philadelphia, Pa, USA, 4th edition, 2005. View at Google Scholar
  39. S. Akira, “TLR signaling,” Current topics in Microbiology and Immunology, vol. 311, pp. 1–16, 2006. View at Google Scholar
  40. H. Y. Reynolds, J. P. Atkinson, H. H. Newball, and M. M. Frank, “Receptors for immunoglobulin and complement on human alveolar macrophages,” Journal of Immunology, vol. 114, no. 6, pp. 1813–1819, 1975. View at Google Scholar
  41. Z. C. Chroneos, R. Abdolrasulnia, J. A. Whitsett, W. R. Rice, and V. L. Shepherd, “Purification of a cell-surface receptor for surfactant protein A,” Journal of Biological Chemistry, vol. 271, no. 27, pp. 16375–16383, 1996. View at Publisher · View at Google Scholar
  42. U. Holmskov, P. Lawson, B. Teisner et al., “Isolation and characterization of a new member of the scavenger receptor superfamily, glycoprotein-340 (gp-340), as a lung surfactant protein-D binding molecule,” Journal of Biological Chemistry, vol. 272, no. 21, pp. 13743–13749, 1997. View at Publisher · View at Google Scholar
  43. A. J. Tenner, S. L. Robinson, and R. A. B. Ezekowitz, “Mannose binding protein (MBP) enhances mononuclear phagocyte function via a receptor that contains the 126,000 Mr component of the C1q receptor,” Immunity, vol. 3, no. 4, pp. 485–493, 1995. View at Publisher · View at Google Scholar
  44. A. Palecanda and L. Kobzik, “Receptors for unopsonized particles: the role of alveolar macrophage scavenger receptors,” Current Molecular Medicine, vol. 1, no. 5, pp. 589–595, 2001. View at Publisher · View at Google Scholar
  45. N. Khalil, O. Bereznay, M. Sporn, and A. H. Greenberg, “Macrophage production of transforming growth factor β and fibroblast collagen synthesis in chronic pulmonary inflammation,” Journal of Experimental Medicine, vol. 170, no. 3, pp. 727–737, 1989. View at Publisher · View at Google Scholar
  46. S.-T. Uh, Y. Inoue, T. E. King Jr., E. D. Chan, L. S. Newman, and D. W. H. Riches, “Morphometric analysis of insulin-like growth factor-1 localization in lung tissues of patients with idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 5, part 1, pp. 1626–1635, 1998. View at Google Scholar
  47. E. J. Campbell, J. D. Cury, C. J. Lazarus, and H. G. Welgus, “Monocyte procollagenase and tissue inhibitor of metalloproteinases. Identification, characterization, and regulation of secretion,” Journal of Biological Chemistry, vol. 262, no. 33, pp. 15862–15868, 1987. View at Google Scholar
  48. J. H. Fisher, V. Sheftelyevich, Y.-S. Ho et al., “Pulmonary-specific expression of SP-D corrects pulmonary lipid accumulation in SP-D gene-targeted mice,” American Journal of Physiology, vol. 278, no. 2, pp. L365–L373, 2000. View at Google Scholar
  49. A. H. Jobe and M. Ikegami, “Surfactant metabolism,” Clinics in Perinatology, vol. 20, no. 4, pp. 683–696, 1993. View at Google Scholar
  50. E. D. Rider, M. Ikegami, and A. H. Jobe, “Localization of alveolar surfactant clearance in rabbit lung cells,” American Journal of Physiology, vol. 263, no. 2, part 1, pp. L201–L209, 1992. View at Google Scholar
  51. T. R. Martin, G. Raugi, T. L. Merritt, and W. R. Henderson Jr., “Relative contribution of leukotriene B4 to the neutrophil chemotactic activity produced by the resident human alveolar macrophage,” Journal of Clinical Investigation, vol. 80, no. 4, pp. 1114–1124, 1987. View at Google Scholar
  52. P. C. Carré, R. L. Mortenson, T. E. King Jr., P. W. Noble, C. L. Sable, and D. W. H. Riches, “Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis,” Journal of Clinical Investigation, vol. 88, no. 6, pp. 1802–1810, 1991. View at Google Scholar
  53. R. E. Smith, R. M. Strieter, K. Zhang et al., “A role for C-C chemokines in fibrotic lung disease,” Journal of Leukocyte Biology, vol. 57, no. 5, pp. 782–787, 1995. View at Google Scholar
  54. T. J. Standiford, M. W. Rolfe, S. L. Kunkel et al., “Macrophage inflammatory protein-1 a expression in interstitial lung disease,” Journal of Immunology, vol. 151, no. 5, pp. 2852–2863, 1993. View at Google Scholar
  55. T. Thepen, G. Kraal, and P. G. Holt, “The role of alveolar macrophages in regulation of lung inflammation,” Annals of the New York Academy of Sciences, vol. 725, no. 1, pp. 200–206, 1994. View at Publisher · View at Google Scholar
  56. P. G. Holt, J. Oliver, N. Bilyk et al., “Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages,” Journal of Experimental Medicine, vol. 177, no. 2, pp. 397–407, 1993. View at Publisher · View at Google Scholar
  57. T. Kawabe, K.-I. Isobe, Y. Hasegawa, I. Nakashima, and K. Shimokata, “Immunosuppressive activity induced by nitric oxide in culture supernatant of activated rat alveolar macrophages,” Immunology, vol. 76, no. 1, pp. 72–78, 1992. View at Google Scholar
  58. M. D. Roth and S. H. Golub, “Human pulmonary macrophages utilize prostaglandins and transforming growth factor β1 to suppress lymphocyte activation,” Journal of Leukocyte Biology, vol. 53, no. 4, pp. 366–371, 1993. View at Google Scholar
  59. S. Gordon, “Alternative activation of macrophages,” Nature Reviews Immunology, vol. 3, no. 1, pp. 23–35, 2003. View at Publisher · View at Google Scholar
  60. A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati, “The chemokine system in diverse forms of macrophage activation and polarization,” Trends in Immunology, vol. 25, no. 12, pp. 677–686, 2004. View at Publisher · View at Google Scholar
  61. K. Takabayshi, M. Corr, T. Hayashi et al., “Induction of a homeostatic circuit in lung tissue by microbial compounds,” Immunity, vol. 24, no. 4, pp. 475–487, 2006. View at Publisher · View at Google Scholar
  62. M. R. Sartippour and G. Renier, “Differential regulation of macrophage peroxisome proliferator-activated receptor expression by glucose: role of peroxisome proliferator-activated receptors in lipoprotein lipase gene expression,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 1, pp. 104–110, 2000. View at Google Scholar
  63. E. Teissier, A. Nohara, G. Chinetti et al., “Peroxisome proliferator-activated receptor a induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-a activation properties,” Circulation Research, vol. 95, no. 12, pp. 1174–1182, 2004. View at Publisher · View at Google Scholar
  64. C.-H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans, “Transcriptional repression of atherogenic inflammation: modulation by PPARδ,” Science, vol. 302, no. 5644, pp. 453–457, 2003. View at Publisher · View at Google Scholar
  65. J. S. Welch, M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass, “PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6712–6717, 2003. View at Publisher · View at Google Scholar
  66. C. Wolfrum, C. M. Borrmann, T. Börchers, and F. Spener, “Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors α- and γ-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2323–2328, 2001. View at Publisher · View at Google Scholar
  67. K. Asada, S. Sasaki, T. Suda, K. Chida, and H. Nakamura, “Antiinflammatory roles of peroxisome proliferator-activated receptor γ in human alveolar macrophages,” American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 2, pp. 195–200, 2004. View at Publisher · View at Google Scholar
  68. R. C. Reddy, V. G. Keshamouni, S. H. Jaigirdar et al., “Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor-? ligands,” American Journal of Physiology, vol. 286, no. 3, pp. L613–L619, 2004. View at Google Scholar
  69. A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, “PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation,” Nature Medicine, vol. 7, no. 1, pp. 48–52, 2001. View at Publisher · View at Google Scholar
  70. K. J. Moore, E. D. Rosen, M. L. Fitzgerald et al., “The role of PPAR-? in macrophage differentiation and cholesterol uptake,” Nature Medicine, vol. 7, no. 1, pp. 41–47, 2001. View at Publisher · View at Google Scholar
  71. L. C. Bell-Parikh, T. Ide, J. A. Lawson, P. McNamara, M. Reilly, and G. A. FitzGerald, “Biosynthesis of 15-deoxy-Δ12,14-PGJ2 and the ligation of PPARγ,” Journal of Clinical Investigation, vol. 112, no. 6, pp. 945–955, 2003. View at Publisher · View at Google Scholar
  72. Y. Urade, M. Ujihara, Y. Horiguchi, K. Ikai, and O. Hayaishi, “The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues,” Journal of Immunology, vol. 143, no. 9, pp. 2982–2989, 1989. View at Google Scholar
  73. M. Alaoui-El-Azher, Y. Wu, N. Havet, A. Israël, A. Lilienbaum, and L. Touqui, “Arachidonic acid differentially affects basal and lipopolysaccharide-induced sPLA2-IIA expression in alveolar macrophages through NF-κB and PPAR-γ-dependent pathways,” Molecular Pharmacology, vol. 61, no. 4, pp. 786–794, 2002. View at Publisher · View at Google Scholar
  74. X. Lian, C. Yan, Y. Qin, L. Knox, T. Li, and H. Du, “Neutral lipids and peroxisome proliterator-activated receptor-γ control pulmonary gene expression and inflammation-triggered pathogenesis in lysosomal acid lipase knockout mice,” American Journal of Pathology, vol. 167, no. 3, pp. 813–821, 2005. View at Google Scholar
  75. J. T. Huang, J. S. Welch, M. Ricote et al., “Interleukin-4-dependent production of PPAR-? ligands in macrophages by 12/15-lipoxygenase,” Nature, vol. 400, no. 6742, pp. 378–382, 1999. View at Publisher · View at Google Scholar
  76. P. R. S. Baker, Y. Lin, F. J. Schopfer et al., “Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands,” Journal of Biological Chemistry, vol. 280, no. 51, pp. 42464–42475, 2005. View at Publisher · View at Google Scholar
  77. T. Cui, F. J. Schopfer, J. Zhang et al., “Nitrated fatty acids: endogenous anti-inflammatory signaling mediators,” Journal of Biological Chemistry, vol. 281, no. 47, pp. 35686–35698, 2006. View at Publisher · View at Google Scholar
  78. C. Yan and H. Du, “Alveolus formation: what have we learned from genetic studies?” Journal of Applied Physiology, vol. 97, no. 4, pp. 1543–1548, 2004. View at Publisher · View at Google Scholar
  79. C. Yan, X. Lian, Y. Li et al., “Macrophage-specific expression of human lysosomal acid lipase corrects inflammation and pathogenic phenotypes in lal-/- mice,” American Journal of Pathology, vol. 169, no. 3, pp. 916–926, 2006. View at Publisher · View at Google Scholar
  80. D. A. Culver, B. P. Barna, B. Raychaudhuri et al., “Peroxisome proliferator-activated receptor ? activity is deficient in alveolar macrophages in pulmonary sarcoidosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 30, no. 1, pp. 1–5, 2004. View at Publisher · View at Google Scholar
  81. A. M. Johann, A. von Knethen, D. Lindemann, and B. Brüne, “Recognition of apoptotic cells by macrophages activates the peroxisome proliferator-activated receptor-γ and attenuates the oxidative burst,” Cell Death and Differentiation, vol. 13, no. 9, pp. 1533–1540, 2006. View at Publisher · View at Google Scholar
  82. N. Singh, R. Webb, R. Adams et al., “The PPAR-? activator, Rosiglitazone, inhibits actin polymerisation in monocytes: involvement of Akt and intracellular calcium,” Biochemical and Biophysical Research Communications, vol. 333, no. 2, pp. 455–462, 2005. View at Publisher · View at Google Scholar
  83. S. Appel, V. Mirakaj, A. Bringmann, M. M. Weck, F. Grünebach, and P. Brossart, “PPAR-γ agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-κB pathways,” Blood, vol. 106, no. 12, pp. 3888–3894, 2005. View at Publisher · View at Google Scholar
  84. M. A. Jakobsen, R. K. Petersen, K. Kristiansen, M. Lange, and S. T. Lillevang, “Peroxisome proliferator-activated receptor α,δ,γ1 and γ2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands,” Scandinavian Journal of Immunology, vol. 63, no. 5, pp. 330–337, 2006. View at Publisher · View at Google Scholar
  85. H. Hammad, H. J. de Heer, T. Soullié et al., “Activation of peroxisome proliferator-activated receptor-? in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma,” American Journal of Pathology, vol. 164, no. 1, pp. 263–271, 2004. View at Google Scholar
  86. V. Angeli, H. Hammad, B. Staels, M. Capron, B. N. Lambrecht, and F. Trottein, “Peroxisome proliferator-activated receptor γ inhibits the migration of dendritic cells: consequences for the immune response,” Journal of Immunology, vol. 170, no. 10, pp. 5295–5301, 2003. View at Google Scholar
  87. E. Imamoto, N. Yoshida, K. Uchiyama et al., “Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells,” BioFactors, vol. 20, no. 1, pp. 37–47, 2004. View at Google Scholar
  88. J. Arias, A. S. Alberts, P. Brindle et al., “Activation of cAMP and mitogen responsive genes relies on a common nuclear factor,” Nature, vol. 370, no. 6486, pp. 226–229, 1994. View at Publisher · View at Google Scholar
  89. R. P. S. Kwok, J. R. Lundblad, J. C. Chrivia et al., “Nuclear protein CBP is a coactivator for the transcription factor CREB,” Nature, vol. 370, no. 6486, pp. 223–226, 1994. View at Publisher · View at Google Scholar
  90. R. Eckner, T.-P. Yao, E. Oldread, and D. M. Livingston, “Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation,” Genes and Development, vol. 10, no. 19, pp. 2478–2490, 1996. View at Publisher · View at Google Scholar
  91. S. Bhattacharya, R. Eckner, S. Grossman et al., “Cooperation of Stat2 and p300/CBP in signalling induced by interferon-a,” Nature, vol. 383, no. 6598, pp. 344–347, 1996. View at Publisher · View at Google Scholar
  92. A. E. Horvai, L. Xu, E. Korzus et al., “Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and P300,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 4, pp. 1074–1079, 1997. View at Publisher · View at Google Scholar
  93. J. J. Zhang, U. Vinkemeier, W. Gu, D. Chakravarti, C. M. Horvath, and J. E. Darnell Jr., “Two contact regions between Stat1 and CBP/p300 in interferon γ signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 26, pp. 15092–15096, 1996. View at Publisher · View at Google Scholar
  94. N. D. Perkins, L. K. Felzien, J. C. Betts, K. Leung, D. H. Beach, and G. J. Nabel, “Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator,” Science, vol. 275, no. 5299, pp. 523–527, 1997. View at Publisher · View at Google Scholar
  95. V. Bocher, I. Pineda-Torra, J.-C. Fruchart, and B. Staels, “PPARs: transcription factors controlling lipid and lipoprotein metabolism,” Annals of the New York Academy of Sciences, vol. 967, pp. 7–18, 2002. View at Google Scholar
  96. F. Chen, M. Wang, J. P. O'Connor, M. He, T. Tripathi, and L. E. Harrison, “Phosphorylation of PPARγ via active ERK1/2 leads to its physical association with p65 and inhibition of NF-κβ,” Journal of Cellular Biochemistry, vol. 90, no. 4, pp. 732–744, 2003. View at Publisher · View at Google Scholar
  97. G. Chinetti, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation,” Inflammation Research, vol. 49, no. 10, pp. 497–505, 2000. View at Publisher · View at Google Scholar
  98. H. Shu, B. Wong, G. Zhou et al., “Activation of PPARa or ? reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells,” Biochemical and Biophysical Research Communications, vol. 267, no. 1, pp. 345–349, 2000. View at Publisher · View at Google Scholar
  99. G. Piraino, J. A. Cook, M. O'Connor et al., “Synergistic effect of peroxisome proliferator activated receptor-? and liver X receptor-a in the regulation of inflammation in macrophages,” Shock, vol. 26, no. 2, pp. 146–153, 2006. View at Publisher · View at Google Scholar
  100. J. B. Seo, H. M. Moon, W. S. Kim et al., “Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor ? expression,” Molecular and Cellular Biology, vol. 24, no. 8, pp. 3430–3444, 2004. View at Publisher · View at Google Scholar
  101. X. Z. Ruan, J. F. Moorhead, R. Fernando, D. C. Wheeler, S. H. Powis, and Z. Varghese, “PPAR agonists protect mesangial cells from interleukin 1β-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway,” Journal of the American Society of Nephrology, vol. 14, no. 3, pp. 593–600, 2003. View at Publisher · View at Google Scholar
  102. R. P. Baughman, A. S. Teirstein, M. A. Judson et al., “Clinical characteristics of patients in a case control study of sarcoidosis,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 10, part 1, pp. 1885–1889, 2001. View at Google Scholar
  103. G. W. Hunninghake, G. N. Bedell, D. C. Zavala, M. Monick, and M. Brady, “Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis,” American Review of Respiratory Disease, vol. 128, no. 4, pp. 634–638, 1983. View at Google Scholar
  104. K. Shigehara, N. Shijubo, M. Ohmichi et al., “IL-12 and IL-18 are increased and stimulate IFN-? production in sarcoid lungs,” Journal of Immunology, vol. 166, no. 1, pp. 642–649, 2001. View at Google Scholar
  105. J. F. Seymour and J. J. Presneill, “Pulmonary alveolar proteinosis: progress in the first 44 years,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 2, pp. 215–235, 2002. View at Publisher · View at Google Scholar
  106. D. W. Golde, M. Territo, T. N. Finley, and M. J. Cline, “Defective lung macrophages in pulmonary alveolar proteinosis,” Annals of Internal Medicine, vol. 85, no. 3, pp. 304–309, 1976. View at Google Scholar
  107. T. Kitamura, N. Tanaka, J. Watanabe et al., “Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor,” Journal of Experimental Medicine, vol. 190, no. 6, pp. 875–880, 1999. View at Publisher · View at Google Scholar
  108. N. Tanaka, J. Watanabe, T. Kitamura, Y. Yamada, S. Kanegasaki, and K. Nakata, “Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor,” FEBS Letters, vol. 442, no. 2-3, pp. 246–250, 1999. View at Publisher · View at Google Scholar
  109. M. S. Kavuru, E. J. Sullivan, R. Piccin, M. J. Thomassen, and J. K. Stoller, “Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 4, part 1, pp. 1143–1148, 2000. View at Google Scholar
  110. J. F. Seymour, J. J. Presneill, O. D. Schoch et al., “Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor patients with idiopathic acquired alveolar proteinosis,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 2, pp. 524–531, 2001. View at Google Scholar
  111. J. C. Gasson, “Molecular physiology of granulocyte-macrophage colony-stimulating factor,” Blood, vol. 77, no. 6, pp. 1131–1145, 1991. View at Google Scholar
  112. D. Metcalf, “Cellular hematopoiesis in the twentieth century,” Seminars in Hematology, vol. 36, no. 4, supplement 7, pp. 5–12, 1999. View at Google Scholar
  113. N. A. Nicola and D. Metcalf, “Specificity of action of colony-stimulating factors in the differentiation of granulocytes and macrophages,” Ciba Foundation Symposium, vol. 118, pp. 7–28, 1986. View at Google Scholar
  114. J. A. Huffman Reed, W. R. Rice, Z. K. Zsengellér, S. E. Wert, G. Dranoff, and J. A. Whitsett, “GM-CSF enhances lung growth and causes alveolar type II epithelial cell hyperplasia in transgenic mice,” American Journal of Physiology, vol. 273, no. 4, part 1, pp. L715–L725, 1997. View at Google Scholar
  115. K. Nakata, K. S. Akagawa, M. Fukayama, Y. Hayashi, M. Kadokura, and T. Tokunaga, “Granulocyte-macrophage colony-stimulating factor promotes the proliferation of human alveolar macrophages in vitro,” Journal of Immunology, vol. 147, no. 4, pp. 1266–1272, 1991. View at Google Scholar
  116. S. Worgall, R. Singh, P. L. Leopold et al., “Selective expansion of alveolar macrophages in vivo by adenovirus-mediated transfer of the murine granulocyte-macrophage colony-stimulating factor cDNA,” Blood, vol. 93, no. 2, pp. 655–666, 1999. View at Google Scholar
  117. D. Krumwieh, E. Weinmann, B. Siebold, and F. R. Seiler, “Preclinical studies on synergistic effects of IL-1, IL-3, G-CSF and GM-CSF in cynomolgus monkeys,” International Journal of Cell Cloning, vol. 8, 1, pp. 229–248, 1990, discussion 247–248. View at Google Scholar
  118. G. Dranoff, A. D. Crawford, M. Sadelain et al., “Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis,” Science, vol. 264, no. 5159, pp. 713–716, 1994. View at Publisher · View at Google Scholar
  119. R. Nishinakamura, A. Miyajima, P. J. Mee, V. L. J. Tybulewicz, and R. Murray, “Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions,” Blood, vol. 88, no. 7, pp. 2458–2464, 1996. View at Google Scholar
  120. L. Robb, C. C. Drinkwater, D. Metcalf et al., “Hematopoietic and lung abnormalities in mice with a null mutation of the common ß subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 21, pp. 9565–9569, 1995. View at Publisher · View at Google Scholar
  121. E. Stanley, G. J. Lieschke, D. Grail et al., “Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 12, pp. 5592–5596, 1994. View at Publisher · View at Google Scholar
  122. T. L. Bonfield, C. F. Farver, B. P. Barna et al., “Peroxisome proliferator-activated receptor-? is deficient in alveolar macrophages from patients with alveolar proteinosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 29, no. 6, pp. 677–682, 2003. View at Publisher · View at Google Scholar
  123. M. Ditiatkovski, B.-H. Toh, and A. Bobik, “GM-CSF deficiency reduces macrophage PPAR-γ expression and aggravates atherosclerosis in ApoE-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 10, pp. 2337–2344, 2006. View at Publisher · View at Google Scholar
  124. P. J. Christensen, R. E. Goodman, L. Pastoriza, B. Moore, and G. B. Toews, “Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell-dependent,” American Journal of Pathology, vol. 155, no. 5, pp. 1773–1779, 1999. View at Google Scholar
  125. J. M. Kaplan, J. A. Cook, P. W. Hake, M. O'Connor, T. J. Burroughs, and B. Zingarelli, “15-deoxy-Δ12,14-prostaglandin J2 (15D-PGJ2), a peroxisome proliferator activated receptor γ ligand, reduces tissue leukosequestration and mortality in endotoxic shock,” Shock, vol. 24, no. 1, pp. 59–65, 2005. View at Publisher · View at Google Scholar
  126. D. Liu, B.-X. Zeng, S.-H. Zhang et al., “Rosiglitazone, a peroxisome proliferator-activated receptor-? agonist, reduces acute lung injury in endotoxemic rats,” Critical Care Medicine, vol. 33, no. 10, pp. 2309–2316, 2005. View at Publisher · View at Google Scholar
  127. M. Peters-Golden, “The alveolar macrophage: the forgotten cell in asthma,” American Journal of Respiratory Cell and Molecular Biology, vol. 31, no. 1, pp. 3–7, 2004. View at Publisher · View at Google Scholar
  128. C. Tang, M. D. Inman, N. van Rooijen et al., “Th type 1-stimulating activity of lung macrophages inhibits Th2-mediated allergic airway inflammation by an IFN-?-dependent mechanism,” Journal of Immunology, vol. 166, no. 3, pp. 1471–1481, 2001. View at Google Scholar
  129. M. Kobayashi, M. J. Thomassen, T. Rambasek et al., “An inverse relationship between peroxisome proliferator-activated receptor ? and allergic airway inflammation in an allergen challenge model,” Annals of Allergy, Asthma & Immunology, vol. 95, no. 5, pp. 468–473, 2005. View at Google Scholar